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The use of thermal energy-based systems to treat uterine ﬁbroids has resulted in a plethora of devices that are less invasive
and potentially as eﬀective in reducing symptoms as traditional options such as myomectomy. Most thermal ablation devices
involve hyperthermia (heating of tissue), which entails the conversion of an external electromagnetic or ultrasound waves into
intracellularmechanicalenergy,generatingheat.Whathasemergedfromtwodecadesofpeer-reviewedresearchistheconceptthat
hyperthermic ﬁbroid ablation, regardless of the thermal energy source, can create large areas of necrosis within ﬁbroids resulting
in reductions in ﬁbroid volume, associated symptoms and the need for reintervention. When a greater percentage of a ﬁbroid’s
volume is ablated, symptomatic relief is more pronounced, quality of life increases, and it is more likely that such improvements
will be durable. We review radiofrequency ablation (RFA), one modality of hyperthermic ﬁbroid ablation.
1.Introduction
Uterineﬁbroids(leiomyomatauteri)arebenignsolidtumors
that are present in the majority of women in the USA by
the age of 50 [1]. While often asymptomatic, ﬁbroids can
result in abnormal uterine bleeding, pelvic pressure, pain,
subfertility, dyspareunia, and other symptoms. Submucous
and intramural ﬁbroids are most associated with heavy men-
strual bleeding (HMB) [2–5]; subserosal ﬁbroids are more
often innocuous unless suﬃciently large so as to contribute
to bulk symptoms. Many ﬁbroids contain elements of more
than one ﬁbroid type; that is, ﬁbroids may have submucous
and subserosal components and may be transmural.
Fibroids are the most common benign female reproduc-
tive system tumor and remain the leading benign indication
for hysterectomy in the USA [6, 7]. Between the years 1990
and 1997, the presence of symptomatic leiomyomata uteri
was the primary diagnosis in 40.2% of all hysterectomies
in the USA [6]. In the UK, ﬁbroids are the second most
common indication for hysterectomy, as approximately 30%
of 42,500 annual hysterectomies are performed for ﬁbroids
[8, 9].
Fibroids have been reported to occur at a rate of 2.0–
9.2 per 1,000 woman-years, and the incidence increases with
age until menopause [7]. Women of African ancestry are at
increased risk for the development of uterine ﬁbroids, with
a reported ﬁbroid incidence of 34.4 per 1,000 woman-years
in this population [7]. By the age of 50, approximately 70%
of white women in the USA will have developed at least one
ﬁbroid, whereas the cumulative incidence was over 80% in
one large study of black women [1].
When symptomatic, uterine ﬁbroids are associated
with a signiﬁcant reduction in health-related quality of life
(HRQOL) as determined by The uterine ﬁbroid symptom
and quality of life questionnaire (UFS-QOL), a validated
ﬁbroid-speciﬁc survey tool [10]. Fibroids also result in a sig-
niﬁcantly greater degree of health care utilization, including
oﬃce and clinic visits. For every woman with ﬁbroids, the
average annual medical cost is $5,989 USD. This is greater
than the $1,846 annual health care cost per woman without
ﬁbroids. If one includes indirect costs, such as the costs
of excess absenteeism and disability claims, the total per-
womancostofﬁbroidsamountsto$8,192eachyear,whichis
2.6timestheannualtotalhealthcarecostforwomenwithout2 Obstetrics and Gynecology International
ﬁbroids [11]. It has been estimated that the total annual
direct cost of ﬁbroids in the USA amounts to $2 billion
[12].
Classic treatment options for symptomatic ﬁbroids
include hysterectomy and myomectomy. More recently,
uterine artery embolization (UAE) has been demonstrated
to be safe and eﬀective, but the impact of this treatment
modality upon fertility remains to be determined [13].
Despite the availability of suitable management choices for
ﬁbroids, there remain unmet needs. Hysterectomy does not
preservetheuterusandfertility,andrepresentsmajorsurgery
with the risk of signiﬁcant complications. Uterine artery
embolization is not currently recommended for women who
desire future fertility, and ﬁbroid recurrence is a possibility,
with approximately 20% of patients subsequently requiring
hysterectomy [14]. Myomectomy, which may be performed
via laparotomy, laparoscopy, hysteroscopy, or occasionally
the vaginal route preserves the uterus and fertility, but like
U A Ei sn o td e ﬁ n i t i v et h e r a p yf o rm a n yw o m e n .
There has been considerable interest in the use of various
forms of energy to heat and ablate uterine ﬁbroids, including
radiofrequency energy, focused ultrasound and microwaves.
Unlike uterine artery embolization, which results in tissue
infarction with disruption of cell membranes and spillage
of intracellular contents, hyperthermic ablation results in
thermal ﬁxation, which preserves cellular architecture, as
well as, coagulative necrosis [15].
Magnetic resonance-guided focused ultrasound (MRg-
FUS) utilizes focused ultrasound waves to heat and ablate
ﬁbroids, leading to ﬁbroid shrinkage and improvement in
ﬁbroid symptoms and quality of life [13, 16–21]. However,
the durability of MRgFUS beyond two years remains to be
established and the availability of the procedure is currently
limited. It is apparent that the clinical results of MRgFUS
have greater signiﬁcance and durability if higher percentages
of the targeted ﬁbroids are ablated [20].
Radiofrequency ablation (RFA) has been extensively
researchedasatreatmentoptionforuterineﬁbroids.Medical
devices utilizing radiofrequency energy are widely available
and familiar to physicians. There is an established history
of treating hepatocellular carcinomata and other soft tissue
malignancies with radiofrequency ablation [22–31]. In the
case of uterine ﬁbroids, the presence of coagulative necrosis
after treatment with RF energy can result in volume reduc-
tion of the myoma and symptomatic relief [15, 32–40].
It has become clear from more than two decades of
clinical evidence that hyperthermic ﬁbroid ablation, regard-
less of the thermal energy source, can create large areas of
necrosis within ﬁbroids that result in improved quality of
life and reductions in ﬁbroid volume, associated symptoms,
and the need for reintervention. It is therefore neither
necessary to perform hysterectomy nor to remove myomata
in order to enhance the health and well-being of women
with symptomatic ﬁbroids. The larger the volume destroyed
within a targeted ﬁbroid, the higher the probability that
treatment will be durable over the long term. While the
threshold ablation volume for treatment durability remains
to be established, it is apparent that when only a small
portion of the ﬁbroid is destroyed through hyperthermic
ablation, the surviving fraction of the ﬁbroid can continue
to grow and symptoms can persist [20].
In this paper, we review the use of radiofrequency abla-
tion in the management of uterine ﬁbroids. All of the current
RF devices have the same impact on ﬁbroids. What diﬀers
among them are their electrode designs (bipolar versus
monopolar, single tine versus multiple tines), how they are
deployed (transabdominally, transcervically, transvaginally),
the technique used for real-time visualization (laparoscopy,
sonography), and the hardware and software that regulates
energy delivery to tissue.
Despite diﬀerences in treatment modalities, it is evident
that hyperthermic energy-based systems can improve a
woman’s quality of life. Nonetheless, there remains an unmet
need for a minimally invasive ﬁbroid treatment that is
amenable to an outpatient setting, involves a short treatment
time and may be performed without the risks of general
anesthesia.
2. Early Approachesto Hyperthermic
Fibroid Ablation
The concept of ablating ﬁbroids with hyperthermic energy,
initially referred to as myoma coagulation or myolysis, was
initially performed using a neodymium-doped yttrium alu-
minum garnet (Nd:YAG) laser to deliver energy to ﬁbroids
via laparoscopy or hysteroscopy, resulting in destruction of
the local vascular supply and subsequent ﬁbroid necrosis
[41–43].
The development of bipolar RF needle electrodes paved
the way for electrosurgical ablation of ﬁbroids via laparo-
scopy. This was initially reported by Gallinat and Lueken
in 1993 using their own device that was suitable for small
ﬁbroids [43]. Goldfarb developed two versions of his own
bipolar needle electrode device, one of which was intended
for coagulation of posterior myomata [44, 45].
In 1995, Goldfarb reported on his experience with RF
ablation in a study of 150 women [45]. Of note, patients
receivedneoadjuvantGnRH-analogues(GnRH-a)foratleast
three months to shrink ﬁbroids at least 25% before ablation;
patients who did not respond to GnRH-a treatment were
oﬀered myomectomy or hysterectomy. An average of 30–50
needle insertions were made into a ﬁbroid, and Goldfarb
r e p o r t e dt h a ta7c mﬁ b r o i d( r e d u c e df r o m1 0c ma f t e rt h e
use of GnRH-a) could be treated in 20–30 minutes. It should
be noted that concomitant with RF ablation, 30% of the
subjects underwent a hysteroscopic endometrial ablation,
20%weretreatedwithhysteroscopicresectionofsubmucosal
ﬁbroids, and 37% had endometrial ablation combined with
hysteroscopic myomectomy. These adjuvant procedures,
along with the use of preoperative GnRH-a, confound
the ability to evaluate the impact of myoma ablation on
bleeding outcomes. That said, Goldfarb reported additional
reductions in ﬁbroid size at six months (as much as 50%),
above what had been accomplished temporarily with GnRH-
atreatment.Noﬁbroidsincreasedinsizeaftertreatment,and
there were few complications. Two women were readmitted,
one for a pelvic abscess requiring hysterectomy and the
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150 patients, only six had pain symptoms suggestive of
ﬁbroiddegeneration,andthesewomenweremanagedexpec-
tantly. Three women underwent second-look laparoscopy,
and all of these had mild pelvic adhesions that were
managed with adhesiolysis; it was felt that there were fewer
adhesions than after Nd:YAG laser ablation. One woman
had been diagnosed preoperatively with a leiomyosarcoma
suggested by the massive growth of a ﬁbroid during GnRH-a
treatment. It was noted that 100% of the 150 women
treated with RF ablation (with or without concomitant
endometrial ablation and/or hysteroscopic myomectomy)
responded to these early attempts at RFA treatment of
uterine myomata, with signiﬁcant reductions in ﬁbroid
size at six months; all subjects were asymptomatic after
treatment.
3.Risks andConcerns AssociatedwithEarly
Methods of HyperthermicFibroid Ablation
Despite good reported eﬃcacy, laser ablation and the early
RF bipolar needle electrodes were not widely utilized. The
transserosal use of bipolar needle electrodes and Nd:YAG
laser energy was associated with serosal injury and abdomi-
nopelvic adhesions, likely due to the multiple passes through
the serosa necessary to adequately treat a single ﬁbroid with
a bipolar array in the absence of real-time uterine imaging.
Goldfarbsuggestedthat,comparedtotheuseoftheNd:YAG
laser, the use of bipolar needle electrodes was associated with
a decreased risk of adhesions based on small case series and
one personal communication [45].
There have also been concerns expressed about uter-
ine rupture during future pregnancies after these original
methods of performing RF ablation of ﬁbroids, albeit
based solely on anecdote. Arcangeli and Pasquarett reported
a single case of uterine rupture at 26 weeks’ gestation
in which the neonate subsequently died from prematu-
rity and anemia [46]. Phillips and colleagues published
their experience with 167 women who underwent either
Nd:YAG laser or bipolar needle hyperthermic ablation
of ﬁbroids, with or without concomitant endomyometrial
resection or hysteroscopic myomectomy; some women also
received neoadjuvant GnRH agonist therapy [47]. Phillips
and colleagues recommended that, because of the potential
for injury to the surrounding myometrium, hyperthermic
ﬁbroid ablation should be considered only on an individ-
ualized basis in women who desire future childbearing.
It is interesting to note, however, that two women in
their study conceived and underwent uncomplicated, full-
term vaginal deliveries. Their warning about hyperther-
mic ﬁbroid ablation (i.e., the older technique of multiple
transserosal punctures without concomitant imaging) is
based on the case report of Arcangeli and Pasquarett,
a personal communication involving two women who
experienced uterine rupture at 32 weeks’ gestation and
at term, respectively, and case reports of uterine rupture
after laparoscopic myomectomy in which electrosurgery
was employed and 3–0 and 4–0 polyglactin sutures were
used for uterine closure. Phillips and colleagues suggested
“the use of these sutures rather than ones with stronger
tensile strength such as 1 or 0 polyglactin may have been
responsible for or have contributed in part to the uterine
rupture.”
Vilos and his colleagues published a report of three
women who conceived against medical advice after
laparoscopic RFA with bipolar needles [48]. One of the three
women successfully delivered at term via Cesarean section.
The two other women experienced uterine rupture at 32
weeks’ and 39 weeks’ gestation, respectively; the premature
fetus did not survive. Vilos also took note of a report by
Wood and colleagues, in which a catastrophic gravid uterine
rupture at 26 weeks’ gestation took place three months after
bipolar RF needle ablation of a fundal ﬁbroid; after repair, a
uteroperitoneal ﬁstula resulted [49].
Even with this very limited literature base, the possibility
of uterine rupture and its attendant consequences remain a
potential concern with the earlier methods of Nd:YAG laser
ablation and bipolar RF needle ablation, performed without
imaging guidance.
4. Volumetric HyperthermicFibroidAblation
One of the limitations of the initial attempts at hyperthermic
ﬁbroid ablation was the inability to determine the extent
of the ablation during surgery. The creation of multiple
ablation sites within a given ﬁbroid is one way to maximize
the ablation volume, which in turn increases the likelihood
that the ﬁbroid will undergo suﬃcient volume reduction
as to prevent symptoms and regrowth in the long term.
However, as performed with a bipolar needle electrode
systempassedthroughtheserosa,thisistimeconsumingand
adhesiogenic,duetotheelectrodegeometryandthemultiple
violations of the serosal tissue. And as mentioned, repetitive,
multiple unguided ablations of uterine ﬁbroids may raise
the possibility of myometrial weakening and future uterine
rupture during pregnancy.
Recent RF energy delivery systems have obviated the
need for multiple repetitive insertions of needle electrodes
through a targeted ﬁbroid in order to achieve an optimal
ablation. Real-time sonography can provide conﬁrmation of
accurate targeting during the procedure, and the ablation
volume can be tailored to an individual ﬁbroid, minimizing
the need to create more than one or two ablations in that
ﬁbroid. This is a volumetric approach to ablation, in which
generally one or two ablations of predictable volume are
created to destroy a desired volume of the targeted ﬁbroid.
The successful application of RF ablation to solid tumors of
the liver and other organs has aﬃrmed the validity of this
approach [50, 51].
Image-guided, volumetric hyperthermic ﬁbroid ablation
thus obviates the use of multiple ablations within a ﬁbroid
in the absence of concurrent imaging with the potential
for unintended and unrecognized ablation of surrounding
myometrium. This creates a new level of safety and pre-
dictability of ﬁbroid ablation with RF devices, and increases
the probability that targeted RFA of uterine ﬁbroids is not
associated with uterine rupture and other eﬀects on future
pregnancy.4 Obstetrics and Gynecology International
5.ClinicalStudies ofVolumetric
Radiofrequency Ablation of Uterine Fibroids
ThefeasibilityofpercutaneousRFablationunderultrasound
guidancewasdemonstratedbyRecaldiniandcolleagues[40].
They treated six women who had up to three symptomatic
submucosal or intramural ﬁbroids 4–6cm in diameter using
a LeVeen coaxial needle electrode. The needle electrode was
placed percutaneously under ultrasound guidance. Outcome
measures included the uterine ﬁbroid symptom and quality
of life questionnaire (UFS-QOL) and ﬁbroid volume reduc-
tion as assessed by contrast-enhanced sonography. Mean
followup was nine months, and median ﬁbroid diameter and
volume were signiﬁcantly reduced from 4.8cm (range, 4.4–
5.2) and 58.57cm3 (range, 44.58–73.58) to 2.3cm (range,
1.2–3.2) and 8.97cm3 (range, 0.90–18.81), respectively. The
median symptom score on the UFS-QOL fell from 47.2
(range, 31.8–67.3) to 5.15 (range, 0–26) and the median
quality of life score increased from 63.92 (range, 37.2–86.0)
to 96.2 (range, 86.3–100.0). Four of the six patients were free
of symptoms.
A followup to the study of Recaldini and colleagues was
published in 2009 by Carraﬁello and colleagues [36]. This
medium-term follow-up report involved eleven women (six
from their previous report) with 1–3 symptomatic ﬁbroids
up to 8cm in diameter. The patients underwent percuta-
neous, transabdominal radiofrequency ablation, again using
aLeVeenneedleelectrode(BostonScientiﬁc)undercontrast-
enhanced transabdominal sonographic guidance. Outcome
measures were the UFS-QOL and ﬁbroid volume reduction.
The mean baseline symptom score was 50.30 (range 31.8–
67.30), and the mean baseline quality of life score was 62
(range 37.20–86.00). The average baseline diameter of the
treated ﬁbroids was 5.5cm (range 4.4cm–8cm) and their
meanvolumewas101.5cm3 (range44.58cm3–278cm3).For
ﬁbroids over six centimeters in diameter (two patients),
two ablations were performed to maximize the volume
of necrosis. Of the eleven women, one woman had two
ﬁbroids, only one of which was treated; the remainder
had a single ﬁbroid. After treatment, contrast-enhanced
sonography indicated complete ablation of all ﬁbroids, as
evidenced by hypovascular necrosis. Mean followup was
nine months (range 3–12 months), during which time
the mean symptom score fell to 13.38 (range 0–67.1) and
the mean quality of life score rose to 90.4 (range 43.8–
100). At the last evaluation, the posttreatment mean ﬁbroid
diameter was 3.0cm (range 1.20cm–4.5cm) and the mean
volume was 18cm3 (range 0.90cm3–47.6cm3). Of note, in
the two subjects with ﬁbroids over 6cm in diameter, the
reported volume reduction was 90% and this was stable at 12
months. Nine of eleven patients (81%) experienced volume
reduction over 65% at six months after treatment. At the last
checkup, six of eleven patients (54%) were asymptomatic,
while symptoms had decreased for another four patients
(36%). Thus, symptom and quality of life scores improved
in 10 of 11 patients (91%). One patient, despite volumetric
reduction, did not experience symptomatic improvement
and underwent hysterectomy. At the time of hysterectomy,
there were no adhesions noted and there were two necrotic
adjacent nodules in the endometrial surface from the
previous ablation. There were no complications noted and
no patient required retreatment. The authors concluded
that this larger cohort with longer followup conﬁrmed
previous papers from their group on the feasibility and
eﬀectiveness of this approach. The feasibility of multiple
electrode deployments and ablations was also highlighted, as
these were not associated with complications.
Bergamini and colleagues used a multitine RF needle ele-
ctrode placedlaparoscopicallyto ablate ﬁbroids in 18 women
with ﬁbroids 5–8.6cm in diameter and 14.8–332.8cm3 in
volume [35]. As opposed to a single needle electrode system,
this multitine device was able to produce a spherical, as
opposed to cylindrical, volume of ablated tissue. A single
insertion was used for ﬁbroids up to 5cm in diameter.
Outcome measures included ﬁbroid volume reduction (as
determined sonographically) and UFS-QOL score; median
followup was 10 months (range 3–12). By month six, the
median ﬁbroid volume decreased by 77% (P<0.01). No
additional signiﬁcant volume reductions were detected after
thattimepoint.Ninewomenwerefollowedoutto12months
and there was no evidence of new growth. Seven of the
nine subjects (77.8%) were symptom free at 12 months after
treatment. At six months, median symptom scores fell from
43.7 (range 12.5–90.6) at baseline to 9.7 (range 1.1–52.8;
P<0.01). Median quality of life scores rose from 66.7 (range
35.0–93.9) at baseline to 100.0 (range 98.2–100; P<0.01) at
six months.
Ghezzi and colleagues provided data on the ﬁrst 25
women treated in their center with a multitine needle
electrode device [38]. All 25 women were assessed at six
months, 24 through one year, 18 through two years, and
9 through three years; median followup was 24 months.
Fibroid measurements were performed with sonography.
Meanﬁbroidvolumeswerereducedby65.6%,77.9%,78.6%,
and 83.9% at 6, 12, 24, and 36 months, respectively. Mean
UFS-QOL symptom severity scores went from a baseline of
43.7to4.7atsixmonthsand0by12months;meansymptom
scores remained at zero through 36 months of followup.
Health-related quality of life (HRQOL) on the same UFS-
QOLquestionnairerosefromamedianbaselinescoreof63.1
to 99.1 at six months and then to 100 at 12 months, which
persisted through 36 months. There were no long-term com-
plications reported. One woman underwent hysterectomy
for recurrent ﬁbroid symptoms at 12 months after treatment
despite a signiﬁcant reduction in ﬁbroid volume.
Cho et al. have employed a single, straight 25cm 18-
gauge radiofrequency ablation needle electrode to manage
symptomatic uterine ﬁbroids [37]. The needle electrode was
generally placed transcervically; the posterior cul-de-sac
or anterior vesicouterine fold was also utilized in selected
subjects. Targeting of selected ﬁbroids was carried out using
either transabdominal or transrectal sonography. Experience
withthissystemhasbeenreportedfor153women,14ofwho
were excluded due to lack of followup. Mean pretreatment
dominant ﬁbroid volume, as determined by sonography, was
65.12cm3; multiple ablations were performed to treat ﬁb-
roids larger than 5cm in diameter. By 18 months, the mean
dominant ﬁbroid volume was 19.3cm3 (73% reduction).Obstetrics and Gynecology International 5
The vast majority of the reduction in dominant ﬁbroid
volume occurred within the ﬁrst 12 months. For ﬁbroids
with a pretreatment volume of 75cm3 or less, mean UFS-
QOL symptom severity scores went from 46.9 to 4.2 at
18 months (P<0.05). Mean health-related quality of life
scores rose from 66.9 to 97.7 at 18 months (P<0.05). Six
women (4.3%) underwent reintervention during this period,
and women with ﬁbroids with a volume >75cc (5.3cm in
diameter) were more likely to require reintervention and
have lower satisfaction scores. It should be noted that of the
six women who were retreated, ﬁve had reintervention prior
to the 12-month followup and the single reintervention at 16
months was due to a de novo ﬁbroid that was asymptomatic
but had a more rapid growth rate. Long-term complications
by 18 months were also uncommon and minor, consisting
of spotting up to 8 weeks after ablation in 9.6% of women.
There were no major complications, such as injury to the
bowel or bladder.
Szydłowska and Starczewski published their experience
with performing radiofrequency ablation of uterine ﬁbroids
in 46 women with a monopolar needle electrode delivered
laparoscopically [34]. Their procedure involved making a
single puncture for ﬁbroids with diameters ≤3cm and two
punctures through the serosa for ﬁbroids > 3cm in diameter,
with three 10-second ablations per puncture. Followup at
six months, which included Doppler velocimetry, produced
striking results. In 73.3% of women who had ﬁbroids with
v o l u m e sl e s st h a n5c m 3(roughly corresponding to diameters
of 2cm and less), their ﬁbroids were undetectable on
sonographic imaging at six months. In the remaining 26.7%
of women with initial ﬁbroid volumes of 5cm3 or less, their
ﬁ b r o i d sw e r er e d u c e di nm e a nv o l u m eb y8 3 .5% (P<0.001).
For women with initial ﬁbroid volumes over 5cm3,4 1 .9%
of subjects had undetectable ﬁbroids at six months, with
75% mean shrinkage noted in the remaining cohort (P<
0.001). Fibroid volume reduction correlated with increases
in the pulsatility index (PI) and resistance index (RI) in
both uterine arteries at six months, signifying a reduction
in blood ﬂow to treated ﬁbroids. There was symptomatic
relief of HMB and/or pelvic pain in 88% of patients by six
months. One subject was refractory to the eﬀects of ﬁbroid
ablation, with no diminution in size of her ﬁbroid and the
appearance of two new ﬁbroids; she was managed with open
myomectomy, and no adhesions were noted at the time of
laparotomy.
Recently, Kim and colleagues have reported results of
RF ablation in 69 women with ﬁbroids up to 12.5cm in
diameter, some of who desired fertility [39]. They used
a single RF needle electrode that was saline cooled, to
prevent carbonization, and inserted it transvaginally under
conscious sedation with transvaginal ultrasound guidance.
In the 10.1% of women who desired future fertility, the
needle electrode was purposely placed so as to avoid the
endometrium. Outcomes were assessed at 1, 3, 6, and 12
months after ablation. Fibroid volumes were measured by
transvaginal sonography, and HMB was evaluated by a
tabulation of the number of soaked normal-sized sanitary
products in a menstrual cycle; overall symptoms were
assessed with the UFS-QOL symptom severity score (SSS)
questionnaire.Thereweresigniﬁcantimprovementsinheavy
menstrual bleeding noted at each assessment (1, 3, 6, and 12
months; all P<0.001 versus baseline). Overall symptoms,
as measured with the UFS-QOL SSS, were also signiﬁcantly
reduced at all assessments. Finally, there were three reported
uncomplicated pregnancies; two normal spontaneous vagi-
nal deliveries and one Cesarean section. This paper by Kim
and colleagues is particularly important as it represents the
ﬁrst bleeding study of any hyperthermic ablation technique,
and also provides pregnancy data (albeit with a very small
population). Given the small number of patients who
became pregnant, it remains unproven if current RF ablation
methods would avoid the occasional cases of uterine rupture
reported after the earlier work with both Nd:YAG laser
and bipolar needle myolysis. That said, the early evidence is
promising.Unliketheearliermethodsofmyomacoagulation
that involved multiple ablations of ﬁbroids without imaging
guidance, today’s volumetric, image-guided ablation permits
the operator to ablate a ﬁbroid with a single ablation in
most cases, and often in a fashion that conﬁnes the ablation
to the myoma and spares the surrounding myometrium
and endometrium. For additional support, there have been
more than 50 reported cases of pregnancy after MRI-guided
focused ultrasound, another form of hyperthermic ablation,
with generally good outcomes and no reports of uterine
rupture [52–55].
Finally, intrauterine ultrasound-guided radiofrequency
ablation of ﬁbroids is a procedure that has been reported
t ob es a f ea n dr e l i a b l ei nac o h o r to f1 9w o m e n[ 56].
This technique involves the use of the VizAblate System,
which combines RF ablation for treatment with intrauterine
sonography for imaging in a single device that is inserted
transcervically.Therewerenocomplicationswhenthedevice
was used to ablate 20 ﬁbroids in the 19 subjects. After
either immediate or delayed (16-17 days after ablation)
total abdominal hysterectomy, the extirpated uteri were
stained with triphenyltetrazolium chloride (a vital stain to
discriminate between viable and nonviable tissue). This vital
staining indicated that in these patients, 67.2% ± 27.0% of
the ﬁbroid volume was successfully ablated (range 15–100%;
median 75%). As noted previously, it is not necessary to
completely ablate ﬁbroids in order to provide symptomatic
relief. An eﬃcacy study involving the VizAblate System is
c u r r e n t l yi np r o g r e s si nE u r o p ea n dM e x i c o .
There has been no reported experience with preoperative
useofGnRHagonistsinthesetting ofRFablation,outsideof
the early experience with what had been termed “myolysis.”
Some recent studies of RF ablation in uterine ﬁbroids
speciﬁcallyexcludedwomenwhohadreceivedGnRHagonist
therapy [37, 38]. That said, there is no obvious reason why
pretreatment with GnRH agonists would not be helpful
when considering large ﬁbroids for treatment with RF
ablation. Large ﬁbroids may pose a challenge for both
ablative and embolizational therapies. It is unclear what
preciselyqualiﬁesaﬁbroidas“large.”Regardless,itisthought
that increased tissue impedence and vascularity may limit
the ability of hyperthermic ablation therapies to destroy
large ﬁbroids, even when multiple, overlapping ablations are
created in a single ﬁbroid [37]. Thus, preoperative use of6 Obstetrics and Gynecology International
GnRH agonists may enable the wider use of RF ablation with
large ﬁbroids.
Reintervention rates, which are perhaps more clinically
meaningful than ﬁbroid volume reduction, have been repor-
ted to be under 10% in several studies from 3–36 months.
[36–38] While additional study is necessary to clarify the
recurrence and reintervention rates after RF ablation of
uterine ﬁbroids, the initial evidence base is favorable.
6. Conclusion
The use of radiofrequency energy has a demonstrable ability
to successfully and safely ablate a range of ﬁbroid volumes.
Earlier management with RF ablation has been limited by
the lack of concurrent imaging and the need for multiple
ﬁbroid punctures resulting in serosal injury, adhesions, and
potential myometrial disruption during pregnancy. More
recent volumetric techniques, in concert with sonography,
minimize the need for multiple punctures through ﬁbroids;
in the case of transcervical or transvaginal RF ablation, the
serosa is entirely avoided.
Hyperthermic ﬁbroid ablation results in thermal ﬁxation
andcoagulativenecrosiswithintheﬁbroid.Whenasuﬃcient
percentage of a ﬁbroid has been ablated, a reduction in
ﬁbroid volume and associated symptoms can be realized.
Such symptomatic relief appears to be durable, but addi-
tional, longer studies are required to more fully ascertain the
reintervention rate after RF ablation of uterine ﬁbroids. The
emerging clinical literature base indicates that patients will
reliably experience signiﬁcant reductions in ﬁbroid volumes
and symptoms as a result of radiofrequency ablation.
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